1 |
Gartel, A. L. and Tyner, A. L. (1998) The growth-regulatory role of p21 (WAF1/CIP1). Prog. Mol. Subcell. Biol. 20, 43-71.
DOI
|
2 |
Glaser, K. B., Staver, M. J., Waring, J. F., Stender, J., Ulrich, R. G. and Davidsen, S. K. (2003) Gene expression profi ling of multiple histone deacetylase (HDAC) inhibitors: defi ning a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2, 151-163.
DOI
|
3 |
Gui, C. Y., Ngo, L., Xu, W. S., Richon, V. M. and Marks, P. A. (2004) Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. USA. 101, 1241-1246.
DOI
ScienceOn
|
4 |
Hortobagyi, G. N. (1998) Treatment of breast cancer. N. Engl. J. Med. 339, 974-984.
DOI
ScienceOn
|
5 |
Johnstone, R. W. and Licht, J. D. (2003) Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 4, 13-18.
DOI
ScienceOn
|
6 |
Joung, K. E., Min, K. N., An, J. Y., Kim, D. K., Kong, G. and Sheen, Y. Y. (2006) Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice. Cancer Res. 66, 5394-5402.
DOI
ScienceOn
|
7 |
Kim, M. S., Blake, M., Baek, J. H., Kohlhagen, G., Pommier, Y. and Carrier, F. (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 63, 7291-8300.
|
8 |
Kim, Y. B., Lee, K. H., Sugita, K., Yoshida, M. and Horinouchi, S. (1999) Oxamfl atin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene. 18, 2461-2470.
DOI
ScienceOn
|
9 |
Komatsu, Y., Tomizaki, K. Y., Tsukamoto, M., Kato, T., Nishino, N., Sato, S., Yamori, T., Tsuruo, T., Furumai R,, Yoshida, M., Horinouchi, S. and Hayashi, H. (2001) Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res. 61, 4459-4466.
|
10 |
Marks, P., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T. and Kelly, W. K. (2011) Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer. 1, 194-202.
|
11 |
Mariadason, J. M., Corner, G. A. and Augenlicht, L. H. (2000) Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 60, 4561-4572.
|
12 |
Nakano, K., Mizuno, T., Sowa, Y., Orita, T., Yoshino, T., Okuyama, Y., Fujita, T., Ohtani-Fujita, N, Matsukawa, Y., Tokino, T., Yamagishi, H., Oka, T., Nomura, H. and Sakai, T. (1997) Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J. Biol. Chem. 272, 22199-22206.
DOI
|
13 |
Papeleu, P., Vanhaecke, T., Elaut, G., Vinken, M., Henkens, T., Snykers, S. and Rogiers, V. (2005) Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance? Crit. Rev. Toxicol. 35, 363-378.
DOI
ScienceOn
|
14 |
Richon, V. M., Sandhoff, T. W., Rifkind, R. A. and Marks, P. A. (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA. 97, 10014-10019.
DOI
ScienceOn
|
15 |
Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T. and Nakanishi, O. (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA. 96, 4592-4597.
DOI
ScienceOn
|
16 |
Sambucetti, L. C., Fischer, D. D., Zabludoff, S., Kwon, P. O., Chamberlin, H., Trogani, N., Xu, H. and Cohen, D. (1999) Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specifi c chromatin acetylation and antiproliferative effects. J. Biol. Chem. 274, 34940-34947.
DOI
ScienceOn
|
17 |
Villar-Garea, A. and Esteller, M. (2004) Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int. J. Cancer 112, 171-178.
DOI
ScienceOn
|
18 |
Sowa, Y., Orita, T., Minamikawa, S., Nakano, K., Mizuno, T., Nomura, H. and Sakai, T. (1997) Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem. Biophys. Res. Commun. 241, 142-150.
DOI
ScienceOn
|
19 |
Suzuki, T., Ando, T., Tsuchiya, K., Fukazawa, N., Saito, A., Mariko, Y., Yamashita, T. and Nakanishi, O. (1999) Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. 42, 3001-3003.
DOI
ScienceOn
|
20 |
Van Lint, C., Emiliani, S. and Verdin, E. (1996) The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5, 245-253.
|
21 |
Vrana, J. A., Decker, R. H., Johnson, C. R., Wang, Z. , Jarvis, W. D., Richon, V. M., Ehinger, M., Fisher, P. B. and Grant, S. (1999) Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene. 18, 7016-7025.
DOI
ScienceOn
|
22 |
Wade, P. A. (2001) Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum. Mol. Genet. 10, 693-698.
DOI
|
23 |
Wittich, S., Scherf, H., Xie, C., Brosch, G., Loidl, P., Gerhäuser, C. and Jung, M. (2002) Structure-activity relationships on phenylalaninecontaining inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. J. Med. Chem. 45, 3296-3309.
DOI
ScienceOn
|
24 |
Yang, X. J. (2004) The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic. Acids. Res. 32, 959-976.
DOI
|
25 |
Blobel, G. A. (2000) CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood. 95, 745-755.
|
26 |
Zhou, Q., Melkoumian, Z. K., Lucktong, A., Moniwa, M., Davie, J. R. and Strobl, J. S. (2000) Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. J. Biol. Chem. 275, 35256-352563.
DOI
|
27 |
Archer, S. Y., Meng, S., Shei, A. and Hodin, R. A. (1998) p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. USA. 95, 6791-6796.
DOI
ScienceOn
|
28 |
Banwell, C. M., Singh, R., Stewart, P. M., Uskokovic, M. R. and Campbell, M. J. (2003) Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation. Recent Results Cancer Res. 164, 83-98.
DOI
|
29 |
Bereshchenko, O. R., Gu, W. and Dalla-Favera, R. (2002) Acetylation inactivates the transcriptional repressor BCL6. Nat. Genet. 32, 606-613.
DOI
ScienceOn
|
30 |
Biswas, S., Criswell, T. L., Wang, S. E. and Arteaga, C. L. (2006) Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy. Clin. Cancer Res. 12, 4142-4146.
DOI
ScienceOn
|
31 |
Brown, R. and Strathdee, G. (2002) Epigenomics and epigenetic therapy of cancer. Trends Mol. Med. 8 (4 Suppl), S43-48.
DOI
ScienceOn
|
32 |
Bulavin, D. V., Phillips, C., Nannenga, B., Timofeev, O., Donehower, L. A., Anderson, C. W., Appella, E. and Fornace, A. J. Jr. (2004) Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat. Genet. 36, 343-350.
DOI
ScienceOn
|
33 |
Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon- Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A. and Richon, V. M. (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60, 5165-5170.
|
34 |
Carron, J. A., Fraser, W. D. and Gallagher, J. A. (1997) PTHrP and the PTH/PTHrP receptor are co-expressed in human breast and colon tumours. Br. J. Cancer. 76, 1095-1098.
DOI
ScienceOn
|
35 |
Chan, H. M., Krstic-Demonacos, M., Smith, L., Demonacos, C. and La Thangue, N. B. (2001) Acetylation control of the retinoblastoma tumour-suppressor protein. Nat. Cell Biol. 3, 667-674.
DOI
ScienceOn
|
36 |
Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K. and Benz, C. C. (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45, 495-528.
DOI
ScienceOn
|
37 |
Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M. and Horinouchi, S. (2001) Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA. 98, 87-92.
DOI
ScienceOn
|